The failure in mid-October of Cantab's (Cambridge, UK) lead vaccine TH-GW for the treatment of genital warts knocked more than two-thirds off the company's share price, forcing the resignation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback